Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
about
Multiple roles for nicotine in Parkinson's diseaseNicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitizationThe CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned ratsFocus on α4β2* and α6β2* nAChRs for Parkinson's Disease Therapeutics.Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors.α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.Role of 5-Hydroxytryptamine 1A Receptors in 6-Hydroxydopmaine-induced Catalepsy-like Immobilization in Rats: a Therapeutic Approach for Treating Catalepsy of Parkinson's Disease.Milestones in Parkinson's disease therapeutics.Targeting nicotinic receptors for Parkinson's disease therapy.Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate.The effect of chronic administration of buspirone on 6-hydroxydopamine-induced catalepsy in rats.An experimental study on intracerebroventricular transplantation of human amniotic epithelial cells in a rat model of Parkinson's disease.Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.Differentiation of hUC-MSC into dopaminergic-like cells after transduction with hepatocyte growth factor.
P2860
Q22252514-BB70FDA2-3AB6-433F-B73F-DCC3C6AB68A4Q30475334-682A1DE4-504B-43C3-80BC-F5262D56D3BFQ34482483-98B21BA2-A24B-46A2-ABBB-F9910F46ADFAQ34793270-5422B883-A274-4B5D-BC4B-1D7FECF99000Q35097046-FD19EE56-73BF-404E-AAC1-AE5E39FDF6A5Q35188119-82D330E3-5C63-4E51-9A87-F147B4845B0AQ35264378-F73D5FF3-5291-4E22-82AD-A6AE43CD74F2Q36936930-75BA7C4D-20A1-4554-A44D-57747C52E2CEQ37268252-2AEA7B42-1972-4921-8949-4F9EA786DE8AQ37882596-EDB2D9FA-E0B5-40A0-B067-E7AF7E680AA3Q37916643-1BAC2910-EBE8-4D04-A0B7-0B7506343FA9Q38101499-C4004D2C-1BF9-4E76-818F-70AC9238C08BQ40790760-282F28CA-0835-4C28-9F07-47773902897AQ42856741-850FA05E-65B7-456E-9E98-55495DB462C3Q43059942-17F9D73A-DBDD-4FC5-98DA-A2BEA418360CQ48210282-FFA35CFF-E265-461A-A636-D8D545978F90Q50936610-F9DE904E-965C-42BB-B165-6D8AC160611F
P2860
Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Parkinson's disease--opportuni ...... problems of levodopa therapy.
@en
Parkinson's disease--opportuni ...... problems of levodopa therapy.
@nl
type
label
Parkinson's disease--opportuni ...... problems of levodopa therapy.
@en
Parkinson's disease--opportuni ...... problems of levodopa therapy.
@nl
altLabel
Parkinson's disease — opportun ...... e problems of levodopa therapy
@en
prefLabel
Parkinson's disease--opportuni ...... problems of levodopa therapy.
@en
Parkinson's disease--opportuni ...... problems of levodopa therapy.
@nl
P1476
Parkinson's disease--opportuni ...... problems of levodopa therapy.
@en
P2093
Rosalind Chuang
P304
P356
10.1016/S0079-6123(08)00923-0
P577
2008-01-01T00:00:00Z